

### **Amendments to the Claims**

This listing of claims will replace all prior versions of the claims and listing of the claims in the application.

#### **Listing of Claims**

1-94. **(Canceled)**

95. **(Previously Presented)** A therapeutic composition, comprising a mixture of the following isolated polypeptides:

(a) an isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6; and

(b) an isolated polypeptide consisting of residues 14-39 of SEQ ID NO:6, or an epitope-containing portion thereof;

wherein said composition is capable of reducing an allergic response to a cat antigen in an individual sensitive to said antigen.

96-101. **(Canceled)**

102. **(Currently Amended)** The composition according to claim 95, wherein at least one of the polypeptides has a stimulation index of at least 4.0 or a positivity index of at least 250, wherein the stimulation index is defined as the ratio of measured proliferation of T cells and antigen presenting cells from a responding individual when exposed to antigen, to the measured proliferation of said cells in the absence of antigen, and wherein the positivity index is defined as the average stimulation index of a population of responding individuals tested multiplied by the percentage of individuals in the population exhibiting a positive response.

103. **(Previously Presented)** The composition according to claim 95, wherein at least one of the polypeptides is produced recombinantly.

104. **(Previously Presented)** The composition according to claim 95, wherein at least one of the polypeptides is produced by chemical synthesis.

105-110. **(Canceled)**

111. **(Currently Amended)** An isolated polypeptide consisting of Fel 31-2 (residues 14-39 of SEQ ID NO:6) ~~and a pharmaceutical acceptable carrier.~~

112. **(Currently Amended)** A composition comprising the polypeptide of claim 111 and a pharmaceutical acceptable carrier.

113. **(Previously Presented)** The composition of claim 112, further comprising a second isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:6.

114. **(Previously Presented)** The composition of claim 111 or 112, further comprising a fragment of a protein allergen comprising the amino acid sequence set forth in SEQ ID NO:6.

115. **(Previously Presented)** The composition of claim 114, wherein the fragment is capable of stimulating T cells.

116. **(New)** The composition of claim 112, further comprising at least one peptide selected from the group consisting of:

Fel 16 (residues 1-22 of SEQ ID NO:6),

Fel 17 (residues 12-33 of SEQ ID NO:6),

Fel 32-1 (residues 12-24 of SEQ ID NO:6),

Fel 32-2 (residues 14-24 of SEQ ID NO:6),

Fel 32-3 (residues 16-24 of SEQ ID NO:6),

Fel 18 (residues 23-48 of SEQ ID NO:6),

Fel 33-1 (residues 26-36 of SEQ ID NO:6),  
Fel 33-2 (residues 26-38 of SEQ ID NO:6),  
Fel 33-3 (residues 26-40 of SEQ ID NO:6),  
Fel 31-1 (residues 14-40 of SEQ ID NO:6),  
Fel 31-3 (residues 14-38 of SEQ ID NO:6),  
Fel 31-4 (residues 14-37 of SEQ ID NO:6),  
Fel 31-5 (residues 14-36 of SE ID NO:6),  
Fel 31-6 (residues 15-40 of SEQ ID NO:6),  
Fel 31-7 (residues 15-36 of SEQ ID NO:6),  
Fel 20-1 (residues 34-59 of SEQ ID NO:6),  
Fel 25 (residues 49-68 of SEQ ID NO:6), and  
Fel 28 (residues 60-82 of SEQ ID NO:6).